Personalised melanoma vaccine cuts recurrence risk in late-stage trial
Adding intismeran to immunotherapy reduced the reported two-year risk of melanoma returning or death by 42% in patients whose tumours had been removed.
Topic
Melanoma Institute Australia
The latest NewsJaws reporting on Melanoma Institute Australia: developments, background and what happens next, with every source linked.
1 NewsJaws report, latest
1 story